Table 1.
Design and characteristics of the trials included in the meta-analysis.
| Source | Publication year | Country | No. of patients | Mean age, y | Percentage male (%) | Disease status | Treatment | Control | Follow-up (months) | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|
| Uchiyama-Tanaka and Mori (10) | 2010 | Japan | 23 | 30.6 | 39.1 | IgA nephropathy | EPA 1.8 g/d plus angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) | ACEi/ARB | 12 | 2 |
| Alexopoulos et al. (11) | 2004 | Greece | 28 | 40.0 | 78.6 | IgA nephropathy | EPA and PHA 5 g/d | Supportive treatment | 48 | 3 |
| Donadio et al. (12) | 2001 | USA | 73 | 45.5 | 52.1 | IgA nephropathy | 2.94 g/d EPA and DHA | 1.47 g/d EPA and DHA | 24 | 4 |
| Donadio et al. (8) | 1999 | USA | 106 | 37.0 | 73.6 | IgA nephropathy | EPA 1.9 g/d plus DHA 1.4 g/d | Placebo | 76.8 | 4 |
| Ferraro et al. (9) | 2009 | Italy | 30 | 40.5 | 60.0 | IgA nephropathy | RASB and PUFAs 3.0 g/dRASB | RASB | 6 | 3 |
| Bennett et al. (13) | 1989 | Australia | 37 | 39.0 | 57.0 | IgA nephropathy | EPA 10 g/d | Untreated | 24 | 4 |
| Pettersson et al. (14) | 1994 | Sweden | 32 | 41.0 | 78.0 | IgA nephropathy | Fish oil 6.0 g/d | Corn oil 6.0 g/d | 6 | 3 |
| Higashihara et al. (15) | 2008 | Japan | 41 | 47.1 | 70.7 | ADPKD | EPA 2.4 g/d | Untreated | 24 | 3 |
| Mori et al. (16) | 2009 | Australia | 74 | 56.5 | 73.0 | CKD | Omega-3 capsules 4 g/d | Olive oil 4.0 g/d | 2 | 4 |